Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
50000 participants
INTERVENTIONAL
2023-09-01
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The South-Norway Atrial Fibrillation Screening Study
NCT04700865
Fibrosis, Inflammation and Brain Health in Atrial Fibrillation.
NCT03816865
Norwegian Study of Persistent Atrial Fibrillation Treatment: Cryoballoon Versus Radiofrequency Catheter Ablation
NCT03008811
Screening for Atrial Fibrillation With Prolonged Continuous Single-lead ECG Devices in High-risk Patients
NCT04519190
SCREENING AFTER STROKE - ATRIAL FIBRILLATION
NCT06675383
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ECG screening
ECG247 is used for continuous screening for 3-7 days
Long-term continuous ECG monitoring
Long-term continuous ECG monitoring with ECG247 Smart Heart Sensor
No ECG screening
Standard of care
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Long-term continuous ECG monitoring
Long-term continuous ECG monitoring with ECG247 Smart Heart Sensor
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent for participation
Exclusion Criteria
* Use of anticoagulation therapy
* Pacemaker/CRT device
* No smart phone
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sorlandet Hospital HF
OTHER_GOV
Haukeland University Hospital
OTHER
St. Olavs Hospital
OTHER
University Hospital of North Norway
OTHER
Oslo University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sigrun Halvorsen
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sigrun Halvorsen, PhD
Role: STUDY_CHAIR
Oslo University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oslo Unvirsity Hospital
Oslo, , Norway
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Boskovic M, Jortveit J, Haraldsen MB, Berge T, Engdahl J, Lochen ML, Schuster P, Sandberg EL, Grimsmo J, Atar D, Anfinsen OG, Pripp AH, Grenne BL, Halvorsen S. The NORwegian atrial fibrillation self-SCREENing (NORSCREEN) trial: rationale and design of a randomized controlled trial. Europace. 2024 Oct 3;26(10):euae228. doi: 10.1093/europace/euae228.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
477781
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.